Courses

Supplement to The American Journal of Cardiology ...
View Course

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and James R. Klinger, will discuss the overall approach to treatment of pulmonary arterial hypertension (PAH), considering diagnosis, patient characterization, treatment algorithms and patient response. Topics such as the history of pulmonary arterial hypertension, challenges of early diagnosis ...
View Course

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT) — the combination of aspirin with an oral P2Y₁₂ receptor antagonist — is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y₁₂ receptor antagonists that are in use are clopidogrel, ...
View Course

The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support.  There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure.  Because acquired methemoglobinemia is rare, clinicians ...
View Course

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy ...
View Course

This CE program will highlight the hospital pharmacist’s role in the management of patients with acute severe hypertension. The expert faculty, led by Paul Szumita, PharmD, will discuss the physiological mechanisms involved in the development of hypertension, global occurrence, and burden of disease for affected individuals. The faculty will review the latest evidence-based data on approaches and techniques for identification ...
View Course

Heart disease continues to be the leading cause of mortality in Europe. Despite advances in prevention and therapy, each year cardiovascular disease (CVD) causes over 1.8 million deaths in the European Union (EU).  CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU, is the main cause of death in men in all ...
View Course

This CE activity will highlight recent advances in the usage of therapeutic agents for the reversal of oral anticoagulants, particularly in patients with life-threatening bleeds. The expert faculty, Dr. Charles V. Pollack Jr., will review emerging therapies for patients with uncontrolled bleeding as well as discuss the latest data on current therapeutic options for the reversal prior to urgent of ...
View Course

This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight advanced strategies for improving cardiovascular disease (CVD) outcomes in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD). The expert faculty, chaired by Dr. Christopher P. Cannon, will first provide an introduction and state of the science ...
View Course

This CME program will highlight recent advances in intensive antiplatelet therapy to improve outcomes in patients with acute coronary syndrome (ACS). The expert faculty, led by Dr. Christopher P. Cannon, will review platelet inhibition science as well as unmet needs in ACS. Following, recent clinical trial data, including outcomes data, will be analyzed and clinical relevance debated in an interactive ...
View Course